Genelux Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
48.1%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.82next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Topline Phase 3 OnPrime/GOG-3076 Ovarian Cancer Trial Data | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
OnPrime/GOG-3076 Phase 3 Trial Enrollment & Events QuarterlyTarget: 127 events for primary PFS analysis
Cash Runway Quarterly26.3MTarget: Fund operations into Q1 2027
Quarterly Net Loss Quarterly-8.9MTarget: Minimize operational cash burn
Watch Items
- Topline data from the randomized Phase 3 OnPrime/GOG-3076 trial for Olvi-Vec in platinum-resistant/refractory ovarian cancerTrigger: Demonstration of clinically meaningful PFS advantage without decrement in OSAction: Prepare and submit Biologics License Application (BLA) for traditional FDA approval
- Interim data readouts from systemically delivered Olvi-Vec lung cancer trials (SCLC and NSCLC)Trigger: Dose-selection updates and objective response rate (ORR) signalsAction: Advance to Phase 2/3 registrational design planning
- Cash position and capital resourcesTrigger: Cash balance falling below $15 million (less than 2 quarters of runway)Action: Execute strategic licensing partnerships or dilutive equity financing to extend runway beyond Q1 2027
Research as of 20 Jun 2026